Apellis Pharmaceuticals Acquired by Biogen | Healthcare M&A Deal

Biogen has acquired Apellis Pharmaceuticals, a pharmaceuticals business in the healthcare sector, for $41.00. Apellis Pharmaceuticals develops therapies in ophthalmology and immunology, supporting a pharmaceuticals acquisition strategy focused on expanding treatment options. Biogen acquisitions in healthcare M&A aim to strengthen its pipeline and commercial reach by adding Apellis’ product platform and late-stage development programs. The merger acquisition is structured as a strategic acquisition and announced deal, with an execution agreement dated March 31, 2026, and closing subject to customary merger conditions and tender offer mechanics.